SCHEMBL25893256

SCHEMBL25893256

COc1ccc([C@H]2c3ccc(OC)cc3OC[C@H]2c2ccc(OC)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ ABCB1 P08183 2/20 0.49
▸ ALDH1A1 P00352 2/20 0.48
▸ ESR1 P03372 2/20 0.47
▸ ESR2 Q92731 2/20 0.47
▸ DRD2 P14416 1/20 0.46
▸ DRD3 P35462 1/20 0.46
▸ CYP3A4 P08684 2/20 0.44
▸ USP2 O75604 1/20 0.44
▸ CYP19A1 P11511 3/20 0.44
▸ ALOX15 P16050 2/20 0.44
▸ ALOX12 P18054 2/20 0.44
▸ KDM1A O60341 2/20 0.44
▸ MAOB P27338 2/20 0.44
▸ MAOA P21397 1/20 0.44
▸ MEN1 O00255 2/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ KDM4E B2RXH2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30362815 1.00 MAPT (0.53) MAPTMAPK1TDP1ABCB1ALDH1A1
SCHEMBL245538 1.00 MAPT (0.53) MAPTMAPK1TDP1ABCB1ALDH1A1
SCHEMBL24103715 1.00 MAPT (0.53) MAPTMAPK1TDP1ABCB1ALDH1A1
SCHEMBL19787655 0.93 ESR1 (0.53) MAPTMAPK1TDP1ABCB1ALDH1A1
SCHEMBL25892444 0.90 MAOB (0.45) MAPTMAPK1TDP1ABCB1ALDH1A1
SCHEMBL25892495 0.90 MAOB (0.45) MAPTMAPK1TDP1ABCB1ALDH1A1
SCHEMBL2604725 0.90 MAOB (0.45) MAPTMAPK1TDP1ABCB1ALDH1A1
SCHEMBL20831829 0.88 ESR1 (0.58) MAPTMAPK1TDP1ALDH1A1ESR1
SCHEMBL20831831 0.88 ESR1 (0.58) MAPTMAPK1TDP1ALDH1A1ESR1
SCHEMBL15312307 0.88 ESR1 (0.58) MAPTMAPK1TDP1ALDH1A1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230233519-A1 COMBINATION THERAPIES Aardvark Therapeutics, Inc. 2023-07-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233519-A1 COMBINATION THERAPIES BCL2, BAK1, BCL2L2 MAPT 2864/4885MAPK1 3494/4885TDP1 1161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback